Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZymeworksZYME +1.68%59 FCF Margin % is -696.03% as of Jun. 2026. GuruFocus rates ZYME with a GF Score™ of 59/100 and a GF Value™ of $15.58 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 953 Biotechnology companies, Zymeworks ranks worse than 52.78% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Zymeworks's Free Cash Flow for the
three
months ended in Jun. 2026 was $-31.95 Mil. Zymeworks's Revenue for the
three
months ended in Jun. 2026 was $4.59 Mil. Therefore, Zymeworks's FCF Margin % for the quarter that ended in Jun. 2026 was -696.03%.
The historical data trend for Zymeworks's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zymeworks's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zymeworks FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zymeworks's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Zymeworks's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (ZYME) has a FCF Margin % of -696.03% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zymeworks and its competitors. According to the industry distribution chart, Zymeworks ranks #503 out of 953 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Zymeworks' FCF Margin % too high?
Zymeworks' current FCF Margin % is -696.03%. Based on the distribution chart, Zymeworks ranks #503 out of 953 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zymeworks has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' FCF Margin % compare to MPLT and SRPT?
According to the Biotechnology industry distribution chart, Zymeworks ranks #503 out of 953 companies for FCF Margin %. This places Zymeworks in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zymeworks and its competitors. Zymeworks's current FCF Margin % is -696.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.58, compared to a current price of $23.54 — trading 51.1% above its estimated fair value. The current FCF Margin % is -696.03%. Zymeworks' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Zymeworks (ZYME), the current FCF Margin % is -696.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zymeworks (ZYME) Overvalued in 2026?
Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued.
The current stock price of $23.54 is trading 51.1% above its estimated GF Value™ of $15.58.
GuruFocus considers Zymeworks to be Significantly Overvalued.
Key valuation signals for ZYME:
FCF Margin %: -696.03%
GF Value™: $15.58 vs. price of $23.54 (51.1% above fair value)
No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
59GF Score
Get the complete analysis for ZYME
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYME has been successfully added to your 
